Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - Citizens JMP analyst reiterated a Market Outperform rating and $33.00 price target on Abivax (NASDAQ:ABVX), a $641.2 million market cap biotech company, following a key opinion leader call that reinforced confidence in the company’s ulcerative colitis treatment. The stock has shown strong momentum, gaining 25% in the past week alone, according to InvestingPro data.
The firm maintained its rating based on potential positive Phase 3 results for obefazimod in moderate-to-severe ulcerative colitis, citing the drug’s promising Phase 2b performance.
Citizens JMP specifically noted the "clear improvement in endoscopy scores and benefit in highly refractory patients" observed in earlier trials as factors supporting their outlook.
The assessment came after Citizens JMP hosted Dr. Marla Dubinsky, a gastroenterologist at Mt. Sinai and inflammatory bowel disease specialist, who expressed encouragement about obefazimod’s prospects based on previous clinical data.
Abivax was identified as one of Citizens JMP’s "two high-conviction names" ahead of upcoming Phase 3 results for its lead drug candidate.
In other recent news, Abivax has successfully completed enrollment for its two Phase 3 induction trials for the drug obefazimod, aimed at treating ulcerative colitis. The company anticipates releasing top-line results from these trials in the third quarter of 2025. Analysts from JMP Securities and Piper Sandler have reiterated their positive outlooks on Abivax, maintaining price targets of $33 and $42, respectively. JMP Securities highlighted the strong efficacy and safety profile demonstrated in earlier trials, while Piper Sandler noted the differentiated profile of obefazimod and its potential for combination use.
Additionally, Abivax has appointed Dr. Dominik Höchli, an immunology expert, to its Board of Directors. Dr. Höchli brings over two decades of experience in the biopharmaceutical industry, including a notable tenure at AbbVie/Abbott. His strategic insights are expected to be pivotal as the company approaches key Phase 3 trial results for obefazimod.
Both JMP Securities and Piper Sandler express confidence in the drug’s potential, with JMP identifying the upcoming clinical data as a significant catalyst. Meanwhile, Abivax continues to emphasize the inherent challenges of clinical development and advises investors to be mindful of the associated risks and uncertainties.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.